RIPK1-IN-38
RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3092834-30-2
- Formule: C27H22FN5O2S
- Masse moléculaire:499.56
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
RIPK1 27 nM (IC50) |
IL-6 |
In Vitro
RIPK1-IN-38 (Compound 2q) (0.01-10 nM; 24 h) can effectively block TSZ/TZ-induced necroptosis in U937, HT-29, and L929 cells, with EC50 values of 0.75 nM, 0.54 nM, and 0.13 nM, respectively[1].
RIPK1-IN-38 (1.25-5 μM; 72 h) exhibits no significant cytotoxicity in HepG2, LX-2, hPBMC, and H9c2 cells[1].
RIPK1-IN-38 (30 nM; 2 h) completely inhibits the phosphorylation of RIPK1, RIPK3, and MLKL in TSZ-treated HT-29 cells[1].
RIPK1-IN-38 (1.25-5 nM; 9 h) significantly inhibits lactate dehydrogenase (LDH) release from necrotic cells in HT-29 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TSZ-treated HT-29 cells
-
Concentration:0.3,3,30,300 nM
-
Incubation Time:2,4,6 h
-
Result:Inhibited the phosphorylation of RIPK1 and its downstream signal proteins RIPK3 and MLKL in a dose- and time-dependent manner.
Parmacokinetics
In Vivo
RIPK1-IN-38 (15-30 mg/kg, oral administration, Days 16-84) significantly alleviates symptoms and increases survival rate in the humanized acute graft-versus-host disease (GVHD) model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (TNF-Induced SIRS model)[1]
-
Dosage:2.5 mg/kg, 5 mg/kg, 10 mg/kg
-
Administration:Oral
-
Result:Exhibited dose-dependent protection from hypothermia.
Improved mouse survival rate and reduce the level of pro-inflammatory cytokine IL-6 in serum.
Reduced inflammatory damage in the liver and kidneys.
-
Animal Model:NOG mice transplanted with human PBMCs (humanized acute GVHD model)[1]
-
Dosage:15 mg/kg, 30 mg/kg
-
Administration:Oral
-
Result:Improved the overall survival rate of mice.
Significantly relieved symptoms such as weak autonomic activity, piloerection, hunchback and weight loss.
Improved colon length and reduced hepatocyte necrosis and periportal lymphocyte infiltration.
Chemical Information
-
CAS No. 3092834-30-2
-
Masse moléculaire 499.56
-
Formule C27H22FN5O2S
-
SMILES
O=C(N[C@@H](C)C1=CC=C(F)C=C1)C2=C3N(C=CC(C4=CC5=C(N=C(NC(C6CC6)=O)S5)C=C4)=C3)N=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)